Key result
Drugs that substantially shorten the QT interval raise proarrhythmic safety concerns and will likely face unfavorable regulatory review unless they fulfill an unmet clinical need.
Design
Review
Authors
Loading...
Supports regulatory caution for QT-shortening drugs; leaves open prospective validation of proarrhythmic risk.
Drug-induced QT interval shortening is a potential harbinger of proarrhythmia that warrants careful regulatory evaluation and potential post-marketing safety monitoring.
Rashmi R. Shah (2009) conducted a review in Drug-induced short QT interval. Drugs that shorten QT interval was evaluated. Drugs that substantially shorten the QT interval raise proarrhythmic safety concerns and will likely face unfavorable regulatory review unless they fulfill an unmet clinical need.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: